Pharmacogenomics

Papers
(The H4-Index of Pharmacogenomics is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
Precision Medicine in Interventional Cardiology: Implications for Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention25
Assessing COVID-19 Susceptibility Through Analysis of the Genetic and Epigenetic Diversity of ACE2-Mediated SARS-CoV-2 Entry25
The Inclusion of Health Data Standards in the Implementation of Pharmacogenomics Systems: A Scoping Review24
Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program22
PGxKnow: A Pharmacogenomics Educational Hololens Application of Augmented Reality and Artificial Intelligence20
Pharmacogenomic Testing to Support Prescribing in Primary Care: a Structured Review of Implementation Models20
Potential of Whole-Genome Sequencing-Based Pharmacogenetic Profiling20
Strategies and Settings of Clinical Pharmacogenetic Implementation: a Scoping Review of Pharmacogenetics Programs19
Effects of the CYP2C19 LoF Allele on Major Adverse Cardiovascular Events Associated with Clopidogrel in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary18
Pharmacogenomics of Oxycodone: A Narrative Literature Review17
Pharmacogenomics in the Uk National Health Service: Opportunities and Challenges16
ATP Binding Cassette Transporters and Cancer: Revisiting Their Controversial Role15
Genetic Susceptibilities and Prediction Modeling of Carbamazepine and Allopurinol-Induced Severe Cutaneous Adverse Reactions in Vietnamese15
The pharmacogenetics of treatment with olanzapine15
Pharmacogenomics Education, Research and Clinical Implementation in the State of Minnesota14
Understanding the Barriers and Enablers of Pharmacogenomic Testing in Primary Care: A Qualitative Systematic Review with Meta-Aggregation Synthesis14
Providers’ Perspectives on the Clinical Utility of Pharmacogenomic Testing in Pediatric Patients14
lncRNA MALAT1 Regulates the Resistance of Breast Cancer Cells to Paclitaxel Via the miR-497-5p/ SHOC2 axis14
Pharmacogenomics in Psychiatry – the Challenge of Cytochrome P450 Enzyme Phenoconversion and Solutions to Assist Precision Dosing14
0.24396300315857